TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02218931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted ESTEEM diet
Description: The key components of the diet are:~High intake of vegetables, nuts, non-refined grains, legumes and fruits;Moderate to high consumption of fish;Small to moderate intake of poultry and dairy products such as yoghurt and cheese;Low consumption of red meat and processed meat and avoidance of sugary drinks, fast food and high fat food;High fibre;Intake of nuts including walnuts and almonds that are rich sources of monounsaturated and polyunsaturated fatty acids (30 g/day);Olive oil to cook and dress salads as the main source of fat (0.5 l/week)~The intervention will include structured meal plans and grocery lists, recipes for healthy diet and appropriate choices at restaurants

Intervention type: OTHER
Group type: OTHER
Intervention: Non-randomised cohort
Description: Non-randomised cohort of women with no metabolic risk factors will be followed up to delivery to collect outcome data
Study: NCT01640158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-based Adaptive Cognitive Training
Description: Computerized plasticity-based adaptive cognitive training, up to 65 hours

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available computerized training
Description: Commercially available computerized training, up to 65 hours
Study: NCT00720954

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ct-guided pleural needle biopsy
Description: Biopsy of pleura

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Thoracoscopy
Description: Biopsy of pleura
Study: NCT02695238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic Manual Rotation of persistent occipital posterior presentation
Description: prophylactic manual rotation of persistent occipital posterior presentation on operative delivery will be performed in the experimental group
Study: NCT00501150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linezolid
Description: Linezolid is an antimicrobial with activity against MRSA that can be given orally.
Study: NCT01420406

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0 mg retinol activity equivalents
Description: 0 mg retinol activity equivalents (RAE) as white-fleshed sweet potatoes and a corn oil capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 mg of BC
Description: 12 mg of BC as orange-fleshed sweet potatoes and a corn oil capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 mg of CX
Description: 6 mg of CX as tangerines and a corn oil capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1.0 mg RAE
Description: 1.0 mg RAE vitamin A as retinyl palmitate in corn oil, and white-fleshed sweet potatoes
Study: NCT03865212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1
Description: Given IT and IV
Study: NCT01496352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFA-02
Description: Modified release product containing gentamicin and vancomycin for application at the conclusion of surgery after closure of the fascia and prior to skin closure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DFA-02 placebo
Study: NCT00931073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon alone
Description: Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon + Ketoconazole
Description: Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 4 during the daily administration of ketoconazole (400 mg, Day 1-11) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon + Omeprazole
Description: Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 5 during the daily administration of omeprazole(40 mg, Day 1-12) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
Study: NCT04538014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF88434
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]-Lu AF88434
Description: \[11C\]-Lu AF88434, and a radioactive dose not exceeding 400 MBq at each PET examination, intravenous bolus injection
Study: NCT03173222

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture
Description: A combined procedure with acupuncture and electric current stimulation. Local electroacupuncture will be given in group EA 1, while local with distal electroacupuncture will be given in group EA 2.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture
Description: A combined procedure with acupuncture and electric current stimulation. Local electroacupuncture will be given in group EA 1, while local with distal electroacupuncture will be given in group EA 2.
Study: NCT00741520

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CPAP
Description: Control - no treatment
Study: NCT02343458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT003)
Description: Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF MDI (PT005)
Description: Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP MDI (PT001)
Description: Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
Study: NCT00741520

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP: The airway pressure will be determined by an overnight sleep study titration.
Study: NCT03568929

Intervention type: DRUG
Intervention: Idelalisib
Description: Tablets administered according to the product information and treatment guidelines in routine clinical practice
Study: NCT02257853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress reduction intervention
Description: Gentle chair yoga and breath work
Study: NCT02116582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Participants received 160 mg of enzalutamide (soft capsules) orally once daily.
Study: NCT00420888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABR-217620/naptumomab estafenatox
Description: 10 mcg/kg or 15 mcg/kg, 5 minute bolus intravenous injection on 4 consecutive days / 8 week cycle repeated 3 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABR-217620/naptumomab estafenatox
Description: 10 mcg/kg or 15 mcg/kg, 5 minute bolus intravenous injection on 4 consecutive days / 8 week cycle repeated 3 times
Study: NCT02343458

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
Study: NCT03491735

Intervention type: OTHER
Intervention: collection of data from patient files
Description: recording of patient data and its input into an excel sheet from which statistics will be derived

Intervention type: OTHER
Intervention: collection of data from patient files
Description: recording of patient data and its input into an excel sheet from which statistics will be derived
Study: NCT00420888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN-alpha
Description: 3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
Study: NCT00647920

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40 mg adalimumab sc, every other week

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo sc, every other week
Study: NCT00420888

Intervention type: DRUG
Group type: OTHER
Intervention: IFN-alpha
Description: 3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
Study: NCT02326103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Comparison of ciprofloxacin with placebo in alcoholic hepatitis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04623294

Intervention type: PROCEDURE
Intervention: Oxygen supply of high-low-high procedure
Description: The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2(phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters.

Intervention type: PROCEDURE
Intervention: Oxygen supply of high-low-high procedure
Description: The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2(phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters.

Intervention type: PROCEDURE
Intervention: Oxygen supply of high-low-high procedure
Description: The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2(phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters.

Intervention type: PROCEDURE
Intervention: Oxygen supply of low-high-low procedure
Description: The protocol consisted of 1- hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters.

Intervention type: PROCEDURE
Intervention: Oxygen supply of low-high-low procedure
Description: The protocol consisted of 1- hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters.

Intervention type: PROCEDURE
Intervention: Oxygen supply of low-high-low procedure
Description: The protocol consisted of 1- hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters.
Study: NCT01043874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: 400 mg BID
Study: NCT00382343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole/trimethoprim
Description: Sulfamethoxazole/trimethoprim prophylaxis
Study: NCT05875324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality application
Description: VR was used for 10 minutes a day in the sitting position for three weeks, twice a week, by watching a walking video before beginning the exercises. Patients were instructed to imagine themselves walking while concentrating on walking and watching the video. The patients were asked to stop watching video by removing their VR glass if they experienced discomfort such as dizziness and nausea during the VR application. They were told to continue watching the video when the discomfort was gone. In cases where similar discomforts recurred, the treatment was terminated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: activities included sitting on the side of the bed and mobilizing in and out of the room using a walker. Patients were provided an exercise program for at-home practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: activities included sitting on the side of the bed and mobilizing in and out of the room using a walker. Patients were provided an exercise program for at-home practice.
Study: NCT03137862

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gluten free bread
Description: patients will receive bread containing 3 g of cornstarch daily for 12 weeks; these patients will serve as controls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten free bread
Description: patients will receive bread containing 3 g of cornstarch daily for 12 weeks; these patients will serve as controls

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten friendly bread 3g/day
Description: patients will have to continue the GFD supplemented with 3 gr of gluten friendly bread daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten friendly bread 6g/day
Description: patients will have to continue the GFD supplemented with 6 gr of gluten friendly bread daily for 12 weeks
Study: NCT01899924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Event Related Potentials recording
Study: NCT02751281

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic percutaneous nephrolithotomy
Description: Pneumatic percutaneous nephrolithotomy is type of surgery that we use pneumatic lithotripter to treat kidney stone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-sonic percutaneous nephrolithotomy
Description: Ultra-sonic percutaneous nephrolithotomy is type of surgery that we use ultra-sonic lithotripter to treat kidney stone
Study: NCT01199081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone
Description: Pharmaceutical form: tablet~Route of administration: oral (together with meal)~Dose regimen: 400 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone
Description: Pharmaceutical form: tablet~Route of administration: oral (together with meal)~Dose regimen: 400 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone
Description: Pharmaceutical form: tablet~Route of administration: oral (together with meal)~Dose regimen: 400 mg twice daily
Study: NCT01640301

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT1-Sensitized Allogeneic T-Lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT1-Sensitized Allogeneic T-Lymphocytes
Description: Given IV
Study: NCT03077282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasaprohyai
Description: Prasaprohyai 95% ethanolic extract capsules will take three times a day before meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasaprohyai
Description: Prasaprohyai 95% ethanolic extract capsules will take three times a day before meals
Study: NCT04510064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus mFLOT regimen
Description: Patients were treated with domestic PD-1 antibody (Camrelizumab for injection) commbined with mFLOT regimen immunotherapy every three weeks, and HER-2 positive patients were added with Herceptin therapy. Camrelizumab 200mg on day 1, albumin bound paclitaxol 125mg/m² on day 1,oxaliplatin 85 mg/m² on day 1, leucovorin 200 mg/m² on day 1, and 5-FU 2600 mg/m² as 24-h infusion on day 1.Herceptin 6mg/Kg at the first time, followed by 4mg/Kg if needed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: R0 surgery
Description: The efficacy of therapy was evaluated every 3 treatment cycles. If the tumor can be R0 resected after 6-9 cycles, then proceeded to surgery. After the operation, patients continued to receive the prior immunotherapy totally to 12 cycles or to the disease progressed or intolerable toxicity.
Study: NCT03043612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook Sof-Flex® Double Pigtail Ureteral Stent coextruded with doxazosin
Description: Placement of drug-coated ureteral stent when temporary ureteral stenting is indicated following ureteroscopy for urolithiasis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cook Sof-Flex® Double Pigtail Ureteral Stent
Description: Placement of a commercially available ureteral stent when temporary ureteral stenting is indicated following ureteroscopy for urolithiasis
Study: NCT00408993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Hydrochloride
Description: 60 mg every day (QD) (morning or evening), by mouth (PO)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo every day (QD), by mouth (PO)
Study: NCT01283789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib and RAD-001
Description: Lapatinib will be taken orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease. Patients will take the tablet at bedtime, at the same time each day, in a fasting state.~Everolimus will be taken orally as a once-daily dose of 5 mg (one 5 mg tablet) from study day 1 until progression of disease. Patients will take the tablet at the same time each morning.
Study: NCT04554862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: magnesium sulfate will be added to the block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: ketorolac will be added to the block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supraclavicular block
Description: it is done by ultrasound- guided

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supraclavicular block
Description: it is done by ultrasound- guided
Study: NCT04932304

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Transcranial direct current stimulation (tDCS)
Description: Sham Transcranial direct current stimulation (tDCS)
Study: NCT04824313

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest CT
Description: Chest CT without intravenous contrast material

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest CTA
Description: Chest CT with intravenous contrast material

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest CTA
Description: Chest CT with intravenous contrast material
Study: NCT04553952

Intervention type: OTHER
Intervention: Measurement of gingival display
Description: All individuals were instructed to sit on a dental chair and the measurements were made by using a millimetric ruler. Next, the patients were grouped according to Liebart's classification by gingival display at maximum smile as follows:~Class 1.Excessive gingival display (Gummy smile): ≥ 3mm gingival display Class 2.High smile line: 0-2 mm of gingival display Class 3. Average smile line: Dental papilla is visible. Class 4. Low smile line: Gingival margin, dental papilla is not visible at all.

Intervention type: OTHER
Intervention: Measurement of gingival display
Description: All individuals were instructed to sit on a dental chair and the measurements were made by using a millimetric ruler. Next, the patients were grouped according to Liebart's classification by gingival display at maximum smile as follows:~Class 1.Excessive gingival display (Gummy smile): ≥ 3mm gingival display Class 2.High smile line: 0-2 mm of gingival display Class 3. Average smile line: Dental papilla is visible. Class 4. Low smile line: Gingival margin, dental papilla is not visible at all.
Study: NCT04381026

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Botanical dry extracts combination
Description: Aframomum melgueta dry extract (50mg), Glycine max bean dry extract (100mg) and Punica granatum skin extract (100mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Filler agent
Study: NCT02754635

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Induction of labour
Description: Induction of labour

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expectant management
Description: Expectant management
Study: NCT00612612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obatoclax mesylate
Description: Given IV
Study: NCT00127192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: sitagliptin phosphate 25 mg, 50 mg, 100 mg QD, or 200 mg QD 12-weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: sitagliptin phosphate 25 mg, 50 mg, 100 mg QD, or 200 mg QD 12-weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: sitagliptin phosphate 25 mg, 50 mg, 100 mg QD, or 200 mg QD 12-weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: sitagliptin phosphate 25 mg, 50 mg, 100 mg QD, or 200 mg QD 12-weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: placebo QD 12-weeks
Study: NCT01456871

Intervention type: PROCEDURE
Intervention: Guided insertion of electrodes
Description: Fine-wire needle electrodes (30mm x 27gauge needle with a pairs of 0.051mm, insulated, hooked wires, Motion Lab Systems, Baton Rouge, LA) guided by sonographic evaluation of the pulley system using a Philips iU22 Ultrasound Machine (Philips Ultrasound Systems, Bothell, WA), a 17-5 MHz linear array transducer, and standard ultrasound gel.

Intervention type: PROCEDURE
Intervention: Electromyographic (EMG) recording
Description: EMG signal recording, performed with an MA 300 EMG system (Motion Lab Systems, Baton Rouge, LA).